Angiex Inc.
Angiex Inc., located in Cambridge, MA, is pioneering the development of first-in-class Nuclear-Delivered Antibody-Drug Conjugates (ND-ADCs) aimed at transforming cancer treatment. With a commitment to making cancer a non-lethal disease, Angiex leverages its innovative technology to deliver effective therapies that address the lethality of solid tumors.
The company is led by experts in tumor blood vessel biology, having discovered VEGF-A, and is currently advancing its lead asset, AGX101, towards clinical trials. Angiex's proprietary Nuclear Delivery Platform is designed to enhance the efficacy and therapeutic margin of cancer therapies by targeting both tumor cells and the endothelial cells of tumor blood vessels.
Generated from the website

